BHCN Stock Chart & Stats
$112.00
$0.00(0.00%)
At close: 4:00 PM EDT
$112.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$83.00 - $136.35
Previous CloseN/A
Volume0.00
Average Volume (3M)26.00
Market Cap
$36.46B
Enterprise Value$30.89K
Total Cash (Recent Filing)$1.82B
Total Debt (Recent Filing)$20.78B
Price to Earnings (P/E)―
Beta-0.21
Next Earnings
Oct 29, 2026EPS Estimate
21.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.95
Shares Outstanding373,990,570
10 Day Avg. Volume0
30 Day Avg. Volume26
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-4.65
Price to Sales (P/S)0.25
P/FCF Ratio2.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$155.06Price Target Upside38.45% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)76.79
Revenue Forecast (FY)$185.36B
Bulls Say, Bears Say
Bulls Say
Raised Guidance And Sustained GrowthRaised guidance, together with 13 consecutive quarters of revenue and adjusted EBITDA growth, indicates improving execution and sustained demand across the business. Higher expected cash generation should support investment and debt reduction, strengthening operating resilience over the next several quarters.
Strong Margins And Cash GenerationA 59% adjusted EBITDA margin and sharply higher operating cash flow demonstrate attractive product economics and meaningful conversion of earnings into liquidity. Sustained cash generation can fund operations internally and provide capacity for gradual deleveraging despite the company’s heavy debt burden.
Growth Across Key Segments And RegionsGrowth in Salix, Solta, and international markets shows that momentum is not confined to a single product or geography. Continued expansion across specialty pharmaceuticals, medical devices, and regions can diversify revenue sources and support a more durable operating base.
Bears Say
Very High Leverage And Negative EquityThe combination of very high debt and negative shareholders’ equity materially limits financial flexibility. Even with improving cash flow and recent net-debt reduction, substantial obligations leave the company sensitive to refinancing costs, operating setbacks, and the need to prioritize debt service.
Xifaxan Exclusivity And IP UncertaintyXifaxan is identified as a major growth driver, so uncertainty around its market exclusivity could materially affect future revenue and EBITDA after 2028. An adverse IP outcome or earlier competition would reduce visibility and challenge the company’s ability to sustain current earnings momentum.
Generic Competition And Reimbursement HeadwindsAplenzin’s loss of exclusivity and ongoing Medicaid/340B erosion create identifiable pressure on realized revenue and margins. These forces can persist beyond a single quarter by reducing pricing or volumes, making it harder for growth and profitability to match the strong first-half performance.
Bausch Health Companies News
BHCN FAQ
What was Bausch Health Companies’s price range in the past 12 months?
Bausch Health Companies lowest stock price was $83.00 and its highest was $136.35 in the past 12 months.
What is Bausch Health Companies’s market cap?
Bausch Health Companies’s market cap is $36.46B.
When is Bausch Health Companies’s upcoming earnings report date?
Bausch Health Companies’s upcoming earnings report date is Oct 29, 2026 which is in 39 days.
How were Bausch Health Companies’s earnings last quarter?
Bausch Health Companies released its earnings results on Jul 29, 2026. The company reported $21.649 earnings per share for the quarter, beating the consensus estimate of $17.088 by $4.56.
Is Bausch Health Companies overvalued?
According to Wall Street analysts Bausch Health Companies’s price is currently Undervalued.
Does Bausch Health Companies pay dividends?
Bausch Health Companies does not currently pay dividends.
What is Bausch Health Companies’s EPS estimate?
Bausch Health Companies’s EPS estimate is 21.61.
How many shares outstanding does Bausch Health Companies have?
Bausch Health Companies has 373,990,570 shares outstanding.
What happened to Bausch Health Companies’s price movement after its last earnings report?
Bausch Health Companies reported an EPS of $21.649 in its last earnings report, beating expectations of $17.088. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Bausch Health Companies?
Currently, no hedge funds are holding shares in MX:BHCN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bausch Health Companies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$155.06 (38.45% Upside)
$155.06 (38.45% Upside)
Blogger Sentiment
Bullish
MX:BHCN Sentiment 67%
Sector Average 63%
Sector Average 63%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Bausch Health Companies
Bausch Health Companies Inc. is a global healthcare enterprise dedicated to the creation, production, and sale of a diverse array of pharmaceutical, medical device, and over-the-counter items. Its primary therapeutic focus areas include eye health, digestive system issues, and dermatological conditions. The company's operations are strategically organized into five key divisions: Bausch + Lomb, which specializes in vision care, surgical solutions, and ophthalmic pharmaceuticals; Salix, concentrating on gastroenterology products within the United States; International Rx, offering a broad portfolio encompassing Solta products, branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across numerous international markets in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East; Ortho Dermatologics, providing dermatological products in the U.S. and Solta medical aesthetic devices globally; and Diversified Products, covering pharmaceutical products in neurology and other therapeutic classes, alongside generic and dentistry items in the United States. Previously known as Valeant Pharmaceuticals International, Inc., the company adopted its current name in July 2018 and maintains its headquarters in Laval, Canada.
BHCN Company Deck
BHCN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum with multiple quarters of consistent top-line and margin expansion, exceptional cash generation, meaningful net-debt reduction, and raised full-year guidance. Management flagged identifiable second-half headwinds (gross-to-net accruals, Aplenzin LOE, gradual Medicaid/340B erosion) and longer-term uncertainties (Xifaxan IP outcome, policy risks), but characterized many drivers of outperformance as transitional. Overall, the positive growth, margin improvement, cash flow strength, and upgraded guidance outweigh the listed challenges.View all MX:BHCN earnings summariesBHCN Revenue Breakdown
47.34% Bausch + Lomb
25.69% Salix
12.23% International
10.77% Diversified Products
3.96% Solta Medical
BHCN Stock 12 Month Forecast
Average Price Target
$155.06
▲(38.45% Upside)